Tiny study probes risks of lung cancer combo therapy
NCT ID NCT03705806
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 12 people with stage IV non-small cell lung cancer who received both palliative chest radiation and an immunotherapy drug (nivolumab or pembrolizumab). The goal was to track side effects like radiation-related toxicities and patient quality of life. Researchers hope to learn how to better manage these combined treatments, but the small size means findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiation therapy (30 Gy in 10 fractions) combined with PD-1 inhibitors (nivolumab or pembrolizumab)
What this could lead to
If successful, this could help doctors better understand and manage side effects when combining radiation and immunotherapy for advanced lung cancer.
What could go wrong
This is a very small observational study (12 people) with no control group, so results may not apply broadly. It only looks at side effects, not whether the combination works better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada